A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies
- 30 November 2003
- journal article
- clinical trial
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 91 (2), 293-298
- https://doi.org/10.1016/s0090-8258(03)00496-7
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian CancerJournal of Clinical Oncology, 2000
- Topotecan Has Substantial Antitumor Activity as First-Line Salvage Therapy in Platinum-Sensitive Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2000
- Gemcitabine–cisplatin: A schedule finding studyAnnals of Oncology, 1999
- A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancerAnnals of Oncology, 1998
- Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivoCancer Chemotherapy and Pharmacology, 1998
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- A Phase I/II Study of Dose-Intense Paclitaxel with Cisplatin and Cyclophosphamide as Initial Therapy of Poor-Prognosis Advanced-Stage Epithelial Ovarian CancerGynecologic Oncology, 1996
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Cancer of the OvaryNew England Journal of Medicine, 1993
- Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.Journal of Clinical Oncology, 1991